PRAMEF11

Across TCGA pan-cancer cohorts, PRAMEF11 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PRAMEF11 data layer compared with 11 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher PRAMEF11 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PRAMEF11 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

ESCA, CESC, and PAAD are the cancer types where PRAMEF11 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	OS	Median	II,III,IV	0.205	0.706	<.001	42	view →
CESC	OS	Median	All	0.387	0.880	<.001	34	view →
PAAD	DFS	Median	All	0.100	0.505	.004	6	view →
UCEC	DFS	Median	All	1.000	0.636	.036	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

PRAMEF11–ESCA (OS)

Open the ESCA breakdown →